Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent Biosolutions (NY: EBS )

4.350 +0.370 (+9.30%)
Streaming Delayed Price Updated: 3:26 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Emergent Biosolutions

< Previous 1 2 3 4 5 6 7 8 9 Next >
See Why Emergent BioSolutions Stock Plunged 37% On Friday?
After a fiasco surrounding the contamination of COVID-19 vaccine doses in its facilities, Emergent BioSolutions Inc's (NYSE: EBS) manufacturing deal with the US... 
Via Benzinga
Exposures COVID-19
Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.57% to 36,331.86 while the NASDAQ rose 0.20% to 15,972.41. The S&P also rose, gaining 0.40% to 4,698.70. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. Trading volume for this security as of 12:30 EST is 1.... 
Via Benzinga
Mid-Day Market Update: Gold Rises 1%; Deciphera Pharmaceuticals Shares Plummet
Midway through trading Friday, the Dow traded up 0.65% to 36,358.13 while the NASDAQ rose 0.48% to 16,016.51. The S&P also rose, gaining 0.58% to 4,707.33. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
64 Stocks Moving In Friday's Mid-Day Session
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the... 
Via Benzinga
Why Emergent Biosolutions Stock Is Crashing Today
The U.S. government canceled a contract related to pandemic preparation. 
Via The Motley Fool
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
Exposures COVID-19 Product Safety
Emergent BioSolutions inc (EBS) Q3 2021 Earnings Call Transcript
EBS earnings call for the period ending October 3, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Assertio Holdings (NASDAQ:ASRT) ... 
Via Benzinga
Millions Of JNJ COVID-19 Shots Sit Idle At Emergent's Baltimore Plant: Reuters
Around 30 million to 50 million doses of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine manufactured earlier this year sit idle in Emergent BioSolutions... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of Moderna's COVID-19 Vaccine Booster Shot For... 
Via Benzinga
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may... 
Via Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate
Emergent BioSolutions Inc (NYSE: EBS) has signed a five-year agreement with Providence Therapeutics valued at about $90 million to develop and... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Moderna Withdraws 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns
More than a million doses of Moderna Inc’s (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
Emergent BioSolutions' COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment
Emergent BioSolutions Inc (NYSE: EBS) has announced the initiation of a Phase 3 trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous... 
Via Benzinga
Exposures COVID-19
Emergent BioSolutions inc (EBS) Q2 2021 Earnings Call Transcript
EBS earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Emergent BioSolutions Stock Higher As COVID-19 Vaccine Production To Resume At Baltimore Plant
Emergent BioSolutions Inc (NYSE: EBS) will resume production of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine at its troubled Baltimore... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
These Companies Have Seen Large Returns From 2020 Government Investment
Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal... 
Via Benzinga
FDA Releases More JNJ's COVID-19 Vaccine Substance From Baltimore Plant
Federal regulators on Friday 
Via Benzinga
Exposures COVID-19 Product Safety
Can Emergent BioSolutions Recover From Its Recent Blunders?
Yes, but it probably won't be an easy path. 
Via The Motley Fool
Exposures COVID-19
Moderna's COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested
Moderna Inc (NASDAQ: MRNA) has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine. The COVID-... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.